Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | HTR2B | P41595 | 3/20 | 0.53 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 2/20 | 0.44 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097607 | 0.79 | HTR2C (0.49) | HTR2CHTR2BHDAC1KDM4EGID4 | |
| SCHEMBL1749514 | 0.77 | HTR2C (0.73) | HTR2CHTR2BHDAC1KDM4ECTSC | |
| SCHEMBL1789145 | 0.76 | HTR2C (0.77) | HTR2CHTR2BHDAC1KDM4ECTSC | |
| SCHEMBL5154669 | 0.76 | HTR2C (0.77) | HTR2CHTR2BHDAC1KDM4ECTSC | |
| SCHEMBL7874030 | 0.76 | HTR2C (0.77) | HTR2CHTR2BHDAC1KDM4ECTSC | |
| SCHEMBL5106986 | 0.76 | HTR2C (0.54) | HTR2CHTR2BHDAC1KDM4E | |
| SCHEMBL5093610 | 0.76 | HTR2C (0.54) | HTR2CHTR2BHDAC1KDM4E | |
| SCHEMBL5100538 | 0.75 | LOXL2 (0.41) | ERCC5FEN1 | |
| Hydrochloric Acid SCHEMBL7607289 | 0.75 | HTR2C (0.75) | HTR2CHTR2BHDAC1KDM4ECTSC | |
| Hydrochloric Acid SCHEMBL18337901 | 0.75 | HTR2C (0.75) | HTR2CHTR2BHDAC1KDM4ECTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417062-B2 | e.g. N (S)-(1-Cyclohexylmethyl-pyrrolidine-2-ylmethyl)-3,4-dimethoxy-N-naphthalen-2-ylmethyl-benzamide; inhibit the binding of the SDF-1 (CXCL12) chemokine or I-TAC (CXCL11) to the chemokine receptor CCXCKR2; anticarcinogenic agent; breast, lymph nodes, bone marrow, and lungs cancer | CHEMOCENTRYX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2006038989-A1 | SUBSTITUTED ARYLAMIDES | CHEMOCENTRYX, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074071-A1 | Substituted arylamides | CHEMOCENTRYX, INC. (US) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074071-A1 | Substituted arylamides | AADAC, BRDT, BRPF3 | HTR2C 318/4885HTR2B 285/4885ERCC5 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.